Clinical Scorecard: In Memoriam: Jesús Saldaña García
At a Glance
Category
Detail
Condition
Preventive cardiology and cardio-oncology focusing on cardiovascular risk stratification and cardiotoxicity prevention
Key Mechanisms
Use of cardiac imaging to detect subclinical disease and guide personalized decision-making; validation of risk scores for anthracycline-related cardiovascular toxicity
Target Population
Patients at risk of cardiovascular disease, including cancer patients receiving cardiotoxic therapies
Care Setting
Cardiology clinical practice and research, including hospital cardiology departments and cardio-oncology units
Key Highlights
Jesús Saldaña García was a promising young cardiologist specializing in preventive cardiology and cardiac imaging.
He contributed to validating the HFA-ICOS risk score for anthracycline-related cardiotoxicity in cardio-oncology.
He combined clinical expertise with advanced statistical skills to improve research quality and clinical data management.
Guideline-Based Recommendations
Diagnosis
Utilize cardiac imaging to refine cardiovascular risk stratification and detect subclinical disease.
Apply validated risk scores such as the HFA-ICOS score to anticipate cardiotoxicity in cancer patients.
Management
Incorporate preventive cardiology principles including personalized decision-making based on imaging findings.
Focus on preserving long-term cardiovascular health in patients undergoing cancer therapies.
Monitoring & Follow-up
Regularly monitor patients receiving cardiotoxic treatments using imaging and risk assessment tools.
Maintain high-quality clinical data to support audits and research for continuous improvement.
Risks
Recognize and mitigate the risk of anthracycline-related cardiovascular toxicity in oncology patients.
Address subclinical cardiovascular disease early to prevent progression.
Patient & Prescribing Data
Patients undergoing cancer therapies with potential cardiotoxic effects
Use of risk stratification tools and imaging to guide preventive interventions and minimize cardiotoxicity.
Clinical Best Practices
Combine clinical judgement with rigorous statistical analysis to enhance research and patient care.
Engage in multidisciplinary collaboration, especially between cardiology and oncology.
Maintain clear communication with patients and families regarding cardiovascular risks and preventive strategies.
